Last reviewed · How we verify
Anti TNF + Meth
Anti TNF + Meth is a TNF inhibitor + DMARD combination Small molecule drug developed by Hamad Medical Corporation. It is currently in Phase 3 development for Rheumatoid arthritis, Other TNF-responsive inflammatory conditions.
This combination therapy blocks tumor necrosis factor (TNF) to suppress inflammatory immune responses while methotrexate inhibits dihydrofolate reductase to reduce cell proliferation and immune activation.
This combination therapy blocks tumor necrosis factor (TNF) to suppress inflammatory immune responses while methotrexate inhibits dihydrofolate reductase to reduce cell proliferation and immune activation. Used for Rheumatoid arthritis, Other TNF-responsive inflammatory conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Anti TNF + Meth |
|---|---|
| Sponsor | Hamad Medical Corporation |
| Drug class | TNF inhibitor + DMARD combination |
| Target | TNF-α receptor / Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Anti-TNF agents (such as monoclonal antibodies or receptor antagonists) neutralize TNF-α, a key pro-inflammatory cytokine, thereby dampening excessive immune responses. Methotrexate acts as a disease-modifying antirheumatic drug (DMARD) by inhibiting folate metabolism and reducing proliferation of activated lymphocytes. The combination leverages complementary mechanisms to achieve enhanced immunosuppression in inflammatory and autoimmune conditions.
Approved indications
- Rheumatoid arthritis
- Other TNF-responsive inflammatory conditions
Common side effects
- Infection (including serious infections)
- Hepatotoxicity
- Bone marrow suppression
- Nausea and gastrointestinal effects
Key clinical trials
- Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti TNF + Meth CI brief — competitive landscape report
- Anti TNF + Meth updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI
Frequently asked questions about Anti TNF + Meth
What is Anti TNF + Meth?
How does Anti TNF + Meth work?
What is Anti TNF + Meth used for?
Who makes Anti TNF + Meth?
What drug class is Anti TNF + Meth in?
What development phase is Anti TNF + Meth in?
What are the side effects of Anti TNF + Meth?
What does Anti TNF + Meth target?
Related
- Drug class: All TNF inhibitor + DMARD combination drugs
- Target: All drugs targeting TNF-α receptor / Dihydrofolate reductase
- Manufacturer: Hamad Medical Corporation — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Other TNF-responsive inflammatory conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing